Literature DB >> 12130949

Epidemiology of Hymenoptera allergy.

Leonardo Antonicelli1, M Beatrice Bilò, Floriano Bonifazi.   

Abstract

PURPOSE OF REVIEW: Epidemiology and especially the natural history of Hymenoptera allergy form the background that is essential to improving the clinical management of insect venom allergic patients. This review focuses on the emergence of recent data which could help provide further enlightenment in this field. RECENT
FINDINGS: The latest data on the extent of the disease, the risk factors for sensitization and for local, systemic and fatal reactions after a hymenoptera sting are reviewed. The emerging problems concerning asymptomatic sensitization, the meaning of constitutively elevated tryptase serum levels and the persisting widespread poor awareness of available therapies in Hymenoptera allergic patients are particularly emphasized.
SUMMARY: The assessment of the risk for systemic reaction in skin-positive subjects with a negative case history, and the suggestion of the baseline serum tryptase level as a risk factor for reaction severity after a sting, are the most important clinical implications of the latest studies. The genetic and environmental factors involved in the persistence of venom specific immunoglobulin E after a sting and the factors which orient towards a systemic or a large local reaction after apparently the same sting remain open questions.

Entities:  

Mesh:

Year:  2002        PMID: 12130949     DOI: 10.1097/00130832-200208000-00008

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  35 in total

Review 1.  Mast Cells and IgE can Enhance Survival During Innate and Acquired Host Responses to Venoms.

Authors:  Stephen J Galli; Philipp Starkl; Thomas Marichal; Mindy Tsai
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

2.  Mast cells and IgE in defense against lethality of venoms: Possible "benefit" of allergy[].

Authors:  Stephen J Galli; Martin Metz; Philipp Starkl; Thomas Marichal; Mindy Tsai
Journal:  Allergo J Int       Date:  2020-03-02

3.  Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay.

Authors:  R Sargur; D Cowley; S Murng; G Wild; K Green; A Shrimpton; W Egner
Journal:  Clin Exp Immunol       Date:  2011-03       Impact factor: 4.330

Review 4.  Fatalities following allergen immunotherapy.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

5.  The neurotoxicological effects of mastoparan Polybia-MPII at the murine neuromuscular junction: an ultrastructural and immunocytochemical study.

Authors:  Thalita Rocha; Bibiana M de Souza; Mario S Palma; Maria Alice da Cruz-Höfling; John Buchanan Harris
Journal:  Histochem Cell Biol       Date:  2009-06-05       Impact factor: 4.304

Review 6.  The Mast Cell-IgE Paradox: From Homeostasis to Anaphylaxis.

Authors:  Stephen J Galli
Journal:  Am J Pathol       Date:  2016-02       Impact factor: 4.307

Review 7.  Testing the 'toxin hypothesis of allergy': mast cells, IgE, and innate and acquired immune responses to venoms.

Authors:  Mindy Tsai; Philipp Starkl; Thomas Marichal; Stephen J Galli
Journal:  Curr Opin Immunol       Date:  2015-07-23       Impact factor: 7.486

Review 8.  IgE and mast cells in host defense against parasites and venoms.

Authors:  Philipp Starkl; Thomas Marichal; Kaori Mukai; Mindy Tsai; Stephen J Galli
Journal:  Semin Immunopathol       Date:  2016-05-25       Impact factor: 9.623

9.  Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.

Authors:  Andrzej Bożek; Krzysztof Kołodziejczyk
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

10.  A beneficial role for immunoglobulin E in host defense against honeybee venom.

Authors:  Thomas Marichal; Philipp Starkl; Laurent L Reber; Janet Kalesnikoff; Hans C Oettgen; Mindy Tsai; Martin Metz; Stephen J Galli
Journal:  Immunity       Date:  2013-10-24       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.